zamaporvint (RXC004) / Redx 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zamaporvint (RXC004) / Redx
ACTRN12624000588594: Clinical study assessing the preliminary efficacy and safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care

Not yet recruiting
2
20
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic Cancer
 
 
PORCUPINE, NCT04907539 / 2020-003132-24: A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Completed
2
25
Europe, US, RoW
RXC004, Nivolumab, Denosumab
Redx Pharma Plc
Colorectal Cancer
04/24
04/24
KEYNOTE-E86, NCT04907851: A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Completed
2
45
Europe, RoW
RXC004, zamaporvint, Denosumab, pembrolizumab, KEYTRUDA®
Redx Pharma Plc, Merck Sharp & Dohme LLC
Advanced Solid Tumours
11/23
11/23
NCT03447470 / 2017-000720-98: Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Completed
1
46
Europe
RXC004, Nivolumab
Redx Pharma Ltd
Cancer, Solid Tumor
09/23
09/23

Download Options